OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ...

In This Article:

Release Date: November 12, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • OncoCyte Corp (NASDAQ:OCX) is making significant progress in democratizing transplant testing, with their technology now being run on three continents.

  • The company has signed leading transplant centers in key markets and is on track to meet or exceed its site placement goal of having 20 sites signed by the end of next year.

  • Demand for the Graf Ruo kit test is exceeding expectations in both Europe and the US, indicating strong market interest.

  • OncoCyte Corp (NASDAQ:OCX) has engaged with the FDA and is preparing for a meeting to discuss their validation plan, showing progress towards regulatory clearance.

  • The company successfully raised $10.2 million in gross proceeds in a private placement, providing financial runway to continue executing on strategic goals.

Negative Points

  • OncoCyte Corp (NASDAQ:OCX) is still largely pre-revenue in the transplant sector, indicating a reliance on future developments for financial growth.

  • The company faces challenges in convincing transplant centers to adopt new technology, as it requires buy-in from both transplant and lab managers.

  • There is a lead-in period expected for new adopters of their IVD product, which could delay revenue generation post-FDA clearance.

  • The company operates in a tough environment for raising capital, which could impact future funding efforts.

  • OncoCyte Corp (NASDAQ:OCX) is navigating a highly competitive market with existing NGS tests, requiring them to differentiate their digital PCR-based assay.

Q & A Highlights

Q: Can you discuss the role that Borra is playing over the next year before potential FDA approval? Are they assisting in opening dialogues with transplant centers or individual physicians? A: (Josh Riggs, CEO) Borra has been very supportive, especially in Germany, where they have strong relationships with labs. This partnership gives us a larger presence and credibility, especially at conferences. In the U.S., they have opened doors where we don't have reach, providing significant support and credibility.

Q: How has the reception been for the Graf Assure workflow among physicians? Is the teaching process intuitive? A: (Josh Riggs, CEO) Most molecular labs are familiar with PCR technology, so the workflow isn't foreign. Training on the Biore platform takes about one to two weeks, and we've had no significant challenges. The process is straightforward, and labs are generating their own data comfortably.

Waiting for permission
Allow microphone access to enable voice search

Try again.